Article

Foldable toric IOL safe and effective in high astigmatism

According to Omid Kermani from the Augenabteilung der PAN-Klinik am Neumarkt, Köln, Germany, and colleagues, the implantation of a foldable toric intraocular lens (IOL) is a safe and predictable procedure for the correction of high pre-existing corneal astigmatism in cataract surgery.

According to Omid Kermani from the Augenabteilung der PAN-Klinik am Neumarkt, Köln, Germany, and colleagues, the implantation of a foldable toric intraocular lens (IOL) is a safe and predictable procedure for the correction of high pre-existing corneal astigmatism in cataract surgery.

A total of 58 eyes were implanted with the MS 6116 TU IOL (HumanOptics) lens during a retrospective study. The IOL has a 6 mm silicon optic with a toric rear surface and the PMMA-haptics are undulated with a Z-shaped design to prevent secondary rotation. Average preoperative astigmatism was 3.75 D.

Postoperatively, astigmatism was reduced to 0.84 D and surgically induced astigmatism was less than 0.5 D in all cases. 85% of the IOLs remained stable within 10° of the target axis. In 5% of the eyes, secondary rotation was performed three to six weeks postoperatively.

Kermani and his colleagues concluded that implantation of HumanOptics' foldable toric IOL is both safe and effective in treating high corneal astigmatism in cataract surgery.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.